Transmitted drug resistance in French HIV-2-infected patients

被引：12

作者：

Charpentier, Charlotte ^{[1
]}

Visseaux, Benoit ^{[1
]}

Benard, Antoine ^{[2
]}

Peytavin, Gilles ^{[3
]}

Damond, Florence ^{[1
]}

Roy, Celine ^{[2
]}

Taieb, Audrey ^{[2
]}

Chene, Genevieve ^{[2
]}

Matheron, Sophie ^{[4
]}

Brun-Vezinet, Francoise ^{[1
]}

Descamps, Diane ^{[1
]}

机构：

[1] Univ Paris 07, Grp Hosp Bichat Claude Bernard, AP HP, HUPNVS,PRES Sorbonne Paris Cite,Lab Virol, Paris, France

[2] Bordeaux Segalen Univ, ISPED, INSERM, U897, Bordeaux, France

[3] Univ Paris 07, Grp Hosp Bichat Claude Bernard, AP HP, HUPNVS,PRES Sorbonne Paris Cite,Lab Pharmacol, Paris, France

[4] Univ Paris 07, Grp Hosp Bichat Claude Bernard, AP HP,HUPNVS,PRES Sorbonne Paris Cite, Serv Malad Infect & Trop, Paris, France

来源：

AIDS | 2013年 / 27卷 / 10期

关键词：

IMMUNODEFICIENCY-VIRUS TYPE-2; HIV-2; INFECTED-PATIENTS; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITORS; MUTATIONS; SURVEILLANCE; PREVALENCE; SUSCEPTIBILITY; MULTICENTER; SELECTION;

D O I：

10.1097/QAD.0b013e32836207f3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report the first transmitted drug resistance survey study in HIV-2-infected patients living in France. The prevalence of transmitted drug resistance was 5.0% (95% confidence interval, 0.1-9.9) with mutations detected only in protease, not in reverse transcriptase. In this series, 10% of patients displayed X4/dual-mixed viruses. These findings classified the rate of transmitted drug resistance in the HIV-2 French Cohort as low prevalence.

引用

页码：1671 / 1674

页数：4

共 26 条

[11] Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda
Eshleman, Susan H.
Laeyendecker, Oliver
Parkin, Neil
Huang, Wei
Chappey, Colombe
Paquet, Agnes C.
Serwadda, David
Reynolds, Steven J.
Kiwanuka, Noah
Quinn, Thomas C.
Grayg, Ronald
Wawer, Maria
[J]. AIDS, 2009, 23 (07) : 845 - 852
[12] HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study
Hamers, Raph L.
Wallis, Carole L.
Kityo, Cissy
Siwale, Margaret
Mandaliya, Kishor
Conradie, Francesca
Botes, Mariette E.
Wellington, Maureen
Osibogun, Akin
Sigaloff, Kim C. E.
Nankya, Immaculate
Schuurman, Rob
Wit, Ferdinand W.
Stevens, Wendy S.
van Vugt, Michele
de Wit, Tobias F. Rinke
[J]. LANCET INFECTIOUS DISEASES, 2011, 11 (10) : 750 - 759
[13] Holzer C, 2004, COMBINATION THERAPY, P195
[14] Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry
Jung, Byung Hwa
Rezk, Naser L.
Bridges, Arlene S.
Corbett, Amanda H.
Kashuba, Angela D. M.
[J]. BIOMEDICAL CHROMATOGRAPHY, 2007, 21 (10) : 1095 - 1104
[15] Factors associated with clinical progression in HIV-2 infected-patients:: The french ANRS cohort
Matheron, S
Pueyo, S
Damond, F
Simon, F
Lepretre, A
Campa, P
Salamon, R
Chêne, G
Brun-Vezinet, F
[J]. AIDS, 2003, 17 (18) : 2593 - 2601
[16] Myatt M, 2008, ANTIVIR THER, V13, P37
[17] Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2
Ntemgwa, Michel L.
Toni, Thomas d'Aquin
Brenner, Bluma G.
Camacho, Ricardo J.
Wainberg, Mark A.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) : 3611 - 3619
[18] Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2
Popper, SJ
Sarr, AD
Travers, KU
Guèye-Ndiaye, A
Mboup, S
Essex, ME
Kanki, PJ
[J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (04) : 1116 - 1121
[19] Raugi DN, 2013, ANTIMICROB AGENTS CH
[20] Transmitted Antiretroviral Drug Resistance in New York State, 2006-2008: Results from a New Surveillance System
Readhead, Adam C.
Gordon, Daniel E.
Wang, Zhengyan
Anderson, Bridget J.
Brousseau, Kathleen S.
Kouznetsova, Maria A.
Forgione, Lisa A.
Smith, Lou C.
Torian, Lucia V.
[J]. PLOS ONE, 2012, 7 (08):

← 1 2 3 →